CCM
NBIX icon

Cadence Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Cadence Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-7,443
Closed -$908K – 364
2020
Q2 		$908K Buy
7,443
+2,870
+63% +$317K 0.13% 235
2020
Q1 		$396K Buy
+4,573
New +$448K 0.07% 343

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Cadence Capital Management's NBIX Position: Q3 2020 in Review

Cadence Capital Management sold out of Neurocrine Biosciences (NBIX) in Q3 2020, closing a stake of 7,443 shares — an estimated $908K sold.

Cadence Capital Management first reported a position in NBIX in Q1 2020 and held it in 2 quarters. The position peaked at $908K in Q2 2020. 418 funds tracked by Wall St. Rank hold NBIX as of Q3 2020.

  • Cadence Capital Management reported no remaining Neurocrine Biosciences position as of Q3 2020 after selling out during the quarter.
  • Cadence Capital Management sold 7,443 Neurocrine Biosciences shares in Q3 2020, an estimated $908K.
  • Cadence Capital Management first reported a position in Neurocrine Biosciences in Q1 2020 and held it in 2 quarters.
  • Cadence Capital Management's Neurocrine Biosciences position peaked at $908K in Q2 2020.
  • 418 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2020.

Based on Cadence Capital Management's 13F filing for Q3 2020, filed 16 Oct 2020.